CAMK2G and Ventricular arrhythmia: AAV9-AIP significantly reduced ventricular arrhythmias in CASQ2−/− mice during epinephrine/challenge (event rate 0.67 vs. 2.17 events/min in controls; p < 0.01). Optical mapping showed normalization of Ca2+ transients and suppression of diastolic Ca2+ waves. Treated cardiomyocytes displayed reduced spontaneous Ca2+ oscillations (27% vs. 79% in untreated; p < 0.01). AIP therapy was well tolerated with no off-target contractility or structural effects, demonstrating efficacy of targeted CaMKII inhibition in genetic arrhythmia.